Top Papers
Gottschlich A, Grünmeier R, Hoffmann GV, Nandi S, Kavaka V, Müller PJ, Jobst J, Oner A, Kaiser R, Gärtig J, Piseddu I, Frenz-Wiessner S, Fairley SD, Schulz H, Igl V, Janert TA, Di Fina L, Mulkers M, Thomas M, Briukhovetska D, Simnica D, Carlini E, Tsiverioti CA, Trefny MP, Lorenzini T, Märkl F, Mesquita P, Brabenec R, Strzalkowski T, Stock S, Michaelides S, Hellmuth J, Thelen M, Reinke S, Klapper W, Gelebart PF, Nicolai L, Marr C, Beltrán E, Megens RTA, Klein C, Baran-Marszak F, Rosenwald A, von Bergwelt-Baildon M, Bröckelmann PJ, Endres S, Kobold S. Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma. Blood. 2025 Apr 3;145(14):1536-1552. doi: 10.1182/blood.2023022197. PMID: 40178843; PMCID: PMC12002222. JIF2024 23.1
Lacher SB, Dörr J, de Almeida GP, Hönninger J, Bayerl F, Hirschberger A, Pedde AM, Meiser P, Ramsauer L, Rudolph TJ, Spranger N, Morotti M, Grimm AJ, Jarosch S, Oner A, Gregor L, Lesch S, Michaelides S, Fertig L, Briukhovetska D, Majed L, Stock S, Busch DH, Buchholz VR, Knolle PA, Zehn D, Dangaj Laniti D, Kobold S, Böttcher JP. PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells. Nature. 2024 May;629(8011):417-425. doi: 10.1038/s41586-024-07254-x. Epub 2024 Apr 24. PMID: 38658748; PMCID: PMC11078747. JIF2024 48.5
Märkl F, Schultheiß C, Ali M, Chen SS, Zintchenko M, Egli L, Mietz J, Chijioke O, Paschold L, Spajic S, Holtermann A, Dörr J, Stock S, Zingg A, Läubli H, Piseddu I, Anz D, Minden MD, Zhang T, Nerreter T, Hudecek M, Minguet S, Chiorazzi N, Kobold S, Binder M. Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia. Nat Commun. 2024 Feb 2;15(1):993. doi: 10.1038/s41467-024-45378-w. PMID: 38307904; PMCID: PMC10837166.
Wagenbauer KF, Pham N, Gottschlich A, Kick B, Kozina V, Frank C, Trninic D, Stömmer P, Grünmeier R, Carlini E, Tsiverioti CA, Kobold S, Funke JJ, Dietz H. Programmable multispecific DNA-origami-based T-cell engagers. Nat Nanotechnol. 2023 Nov;18(11):1319-1326. doi: 10.1038/s41565-023-01471-7. Epub 2023 Aug 17. PMID: 37591933; PMCID: PMC10656288. JIF2024 34.9
Gottschlich A, Thomas M, Grünmeier R, Lesch S, Rohrbacher L, Igl V, Briukhovetska D, Benmebarek MR, Vick B, Dede S, Müller K, Xu T, Dhoqina D, Märkl F, Robinson S, Sendelhofert A, Schulz H, Umut Ö, Kavaka V, Tsiverioti Ch, Carlini E, Nandi S, Strzalkowski T, Lorenzini T, Stock S, Müller P, Dörr J, Seifert M, Cadilha B, Brabenec R, Röder N, Rataj F, Nüesch M, Modemann F, Wellbrock J, Fiedler W, Kellner Ch, Beltrán E, Herold T, Paquet D, Jeremias I, von Baumgarten L, Endres S, Subklewe M, Marr C, Kobold S.
Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia.
Nature Biotechnology 2023; 2023 Mar 13.
JIF2021 68.2
Briukhovetska D, Suarez-Gosalvez J, Voigt C, Markota A, Giannou A, Schuebel M, Jobst J, Zhang T, Doerr J, Mearkl F, Majed L, Meuller PJ, May P, Gottschlich A, Tokarew N, Leucke J, Oener A, Schwerdtfeger M, Andreu-Sanz D, Gruenmeier R, Seifert M, Michaelides S, Hristov M, Koenig LM, Cadilha B, Mikhaylov O, Anders HJ, Rothenfusser S, Flavell R, Cerezo-Wallis D, Tejedo C, Soengas M, Bald T, Huber S, Endres S, Kobold S.
T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis.
Immunity 2023; 143-161.e11.
JIF2021 43.5
https://pubmed.ncbi.nlm.nih.gov/36630913/
Boehmer D, Formisano S, de Oliveira Mann C, Mueller S, Kluge M, Metzger P, Rohlfs M, Hörth Ch, Kocheise L, Lichtenthaler S, Hopfner KP, Endres S, Rothenfusser S, Friedel C, Duewell P, Schnurr* M, Koenig* L.
OAS1/RNase L executes RIG-I ligand-dependent tumor cell apoptosis.
Science Immunology 2021; 61, eabe2550.
JIF2021 30.6
https://immunology.sciencemag.org/content/6/61/eabe2550
https://www.lmu-klinikum.de/aktuelles/pressemitteilungen/programmierter-zelltod-von-tumorzellen-durch-synthetische-rna-molekule/3b1205f11defadda
Di Pilato M*, Kfuri-Rubens R*, Pruessmann J*, Ozga AJ*, Messemaker M, Cadilha B, Sivakumar R, Cianciaruso Ch, Warner RD, Marangoni F, Carrizosa E, Lesch S, Billingsley J, Perez-Ramos D, Zavala F, Rheinbay E, Luster AD, Gerner MY, Kobold S, Pittet MJ, Mempel TR.
CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment.
Cell 2021, 184:4512-30.
JIF2021 66.8
https://www.sciencedirect.com/science/article/abs/pii/S0092867421008564?dgcid=coauthor
*contributed equally
Lesch S, Blumenberg V, Stoiber S, Gottschlich A, Ogonek J, Cadilha B, Dantes Z, Rataj F, Dorman K, Lutz J, Karches C, Heise C, Kurzay M, Larimer B, Grassmann S, Rapp M, Nottebrock A, Kruger S, Tokarew N, Metzger P, Hoerth Ch, Benmebarek MR, Dhoqina D, Gruenmeier R, Seifert M, Oener A, Umut Ö, . . . Rothenfusser S, Duewell P, Koenig L, Schnurr M, Subklewe M, Liss A, Halama N, Reichert M, Mempel T, Endres S, Kobold S.
T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours
Nature Biomedical Engineering 2021; 35:2243-2257.
JIF2020 29.2
https://www.nature.com/articles/s41551-021-00737-6
https://www.lmu-klinikum.de/aktuelles/pressemitteilungen/neue-strategie-gegen-bauchspeicheldrusenkrebs/f95d2c0d7ad55197
Kobold* S, Grassmann* S, Chaloupka M, Lampert C, Wenk S, Kraus F, Rapp M, Duewell P, Zeng Y, Schmollinger J, Schnurr M, Endres S#, Rothenfußer S#.
Impact of a new fusion receptor on PD-1-mediated immunosuppression in adoptive T cell therapy.
The Journal of the National Cancer Institute 2015; 107.
JIF 15.2
Kobold S, Steffen J, Chaloupka M, Grassmann S, Henkel J, Castoldi R, Zeng Y, Chmielewski M, Schmollinger J, Schnurr M, Rothenfußer S, Schendel DJ, Abken H, Sustmann C, Niederfellner CG, Klein C, Bourquin C, Endres S.
Selective bispecific T cell recruiting antibody enhances anti-tumor activity of adoptive T cell transfer.
The Journal of the National Cancer Institute 2015; 107:364.
JIF 15.2
Poeck H, Bscheider M, Gross O, Finger K, Roth S, Rebsamen M, Hannesschläger N, Schlee M, Rothenfusser S, Barchet W, Kato H, Akira S, Inoue S, Endres S, Peschel C, Hartmann G, Hornung V, Ruland J.
Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production.
Nature Immunology 2010; 11:63-9
JIF 26.2
Gross O, Poeck H, Bscheider M, Dostert C, Hannesschlaeger N, Endres S, Tardivel A, Tschopp J, Ruland J.
Syk kinase signaling couples to the Nalp3 inflammasome for anti-fungal host defense.
Nature 2009; 459:433-6
JIF 38.6
Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, Kato H, Poeck H, Akira S, Conzel-mann KK, Schlee M, Endres S, Hartmann G.
5’-triphosphate RNA is the ligand for RIG-I.
Science 2006; 314:994-997.
JIF 35.3
Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de Fougerolles A, Endres S, Hartmann G.
Sequence-specific potent induction of IFN-a by short interfering RNA in plasmacytoid dendritic cells through TLR7.
Nature Medicine 2005; 11:263-70.
JIF 30.6
